Brittany L. Hayes, Ph.D. speaks at DCAT 2024 about Corden Pharma Highly Potent & Oncology Platform Highlights, focused on 3 main areas:
In the past year Corden Pharma launched their Drug Product Innovation Centre of Excellence at our CordenPharma Plankstadt (DE) facility, where they added bioavailability technologies like Hot Melt Extrusion (HME), spray drying, nanomilling and micronization. In addition, they have capabilities to take gram quantities of APIs to make small-scale prototypes for tablets or capsules, and using our Accelerated Stability Assessment Program, quickly identify and predict stability to bring your project rapidly into First-in-Human (FIH).
Secondly, they anticipate the opening of our new clinical trial area in Plankstadt, where they have the capacity to produce 5-60 Kilo batches of tablets and capsules using technologies such as wet and dry granulation, compression coating, and a state-of-the-art encapsulator with filling modules for direct API into individually weighed capsules, as well as powders, granules, pellets, and minitablets.
Lastly, in conjunction with their bioavailability enhancement technologies for non-GMP and long track record of experience with complex formulations, they are expanding into the oral solid dosage formulation of peptides. This exciting area provides oral ingestion of peptides via capsules or tablets, which offers definite advantages over traditional auto-injectors for your patients.